Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics · PIK3CA-Related Overgrowth Spectrum

Diagnostic Testing & Pathology: Getting the Right Answers

At a Glance

Because PROS can affect only certain patches of tissue, a normal blood test does not rule it out. Sensitive sequencing of an affected sample can help confirm the diagnosis, while MRI maps the overgrowth and the variant allele fraction describes the sample rather than disease severity.

Getting a clear answer for Segmental Progressive Overgrowth often requires a tailored approach. Because the condition is mosaic—meaning the genetic change is only in specific parts of the body—standard testing is sometimes the wrong tool for the job [1][2]. Diagnosis integrates physical examination, imaging, and molecular testing.

Why Blood Tests Often Fail

In many genetic conditions, every cell in the body carries the same mutation, so a simple blood draw provides all the answers. However, in PROS, the mutation happened in a single cell after the egg was fertilized [2]. As that cell divided, it created a “patch” of affected tissue while the rest of the body remained typical.

Because the mutation may not be present in the blood at all, a blood test can come back “normal” or “negative” even when the condition is clearly present [3][4]. A negative blood test does not mean you do not have PROS. Testing the affected tissue—such as a small skin biopsy, hair follicles from the affected area, or tissue removed during a previous surgery—often has a higher diagnostic yield [1][5]. However, biopsies carry risks like pain, bleeding, and lymphatic complications. Tissue testing should preferably be selected and interpreted by a vascular-anomalies/genetics team, using tissue obtained during a clinically indicated procedure when possible rather than performing an invasive biopsy solely for testing.

The Role of Advanced Imaging

While genetics confirm the cause, imaging maps the extent. Your medical team will likely use specialized scans selected according to the clinical question:

  • MRI: This is generally preferred for mapping regional soft tissue (fibroadipose hyperplasia). It allows doctors to see exactly where the extra fat and fibrous tissue are located. Contrast is sometimes used depending on the specific examination [6][7].
  • MRA (Magnetic Resonance Angiography): This scan focuses on the arteries to check for any “fast-flow” malformations [8][9].
  • MRV (Magnetic Resonance Venography): This scan maps venous anatomy. It helps identify slow-flow venous malformations, though it does not by itself determine clot risk [10][9].
  • Doppler Ultrasound: Useful for superficial lesions and suspected thrombosis. Note that flow classification from imaging does not independently exclude PROS.

Reading the Pathology Report

When you receive the genetic report, it can look like an intimidating wall of code. However, a comprehensive report for PROS should include several specific data points.

One of the most important terms you will see is Variant Allele Fraction (VAF) [1]. This is the proportion of sequencing reads carrying a variant in that specific sample. It is not a direct count of the percentage of affected cells in the body; copy number, sample purity, and assay design influence it. In PROS, the VAF can be very low because the sample contains a mix of both typical cells and mutated cells [1][11]. It is important to know that VAF helps characterize the sample but cannot reliably grade disease severity or predict the long-term extent of the overgrowth [11][12].

Pathology Completeness Checklist

To ensure a thorough diagnostic workup, discuss these elements with your genetics team:

  • Tissue Source: It should state exactly where the sample came from (e.g., “Left thigh skin biopsy”) [1].
  • Gene Tested: It should explicitly name the PIK3CA gene [13].
  • Method: It should mention High-Depth Next-Generation Sequencing (NGS) or Ultradeep Sequencing to find low-level mosaicism [14].
  • Assay Sensitivity: Rather than judging a test by one depth number (like 500x or 1000x), ask for the laboratory’s validated mosaic-variant detection limit [14].
  • Variant Allele Fraction (VAF): The report should list the proportion of reads for the mutation [1].
  • Clinical Interpretation: A summary from a geneticist explaining how this specific mutation matches the physical symptoms [2].

If the blood test is negative but symptoms point to PROS, talk to your specialist about evaluating affected tissue.

Common questions in this guide

Can a normal blood test rule out PIK3CA-related overgrowth spectrum?
No. PROS can be mosaic, meaning the genetic change is present in some affected tissues but not in blood, so a blood result may be negative even when the condition is present. A genetics or vascular-anomalies team can discuss whether testing an affected tissue sample is appropriate.
Which sample is most useful for PROS genetic testing?
An affected skin sample, hair follicles from the overgrown area, or tissue removed during a clinically indicated surgery may detect the change more reliably than blood. The sample should be chosen with a genetics or vascular-anomalies team because a biopsy can cause pain, bleeding, or lymphatic complications. The report should identify exactly where the sample came from.
What does VAF mean on a PROS genetic report?
Variant allele fraction, or VAF, is the proportion of sequencing reads in a particular sample that contains the variant. It is not the percentage of affected cells in the body and cannot reliably predict disease severity or future extent. Copy number, sample purity, and the laboratory method can affect the result.
Why might my doctor order MRI, MRA, or MRV for PROS?
MRI maps regional soft-tissue and fibroadipose overgrowth. MRA examines arteries for fast-flow abnormalities, while MRV maps veins for slow-flow venous malformations; MRV alone does not determine clot risk. Doppler ultrasound may help evaluate superficial lesions or suspected thrombosis.
What should a complete PROS pathology or genetic report include?
It should identify the tissue source, name the PIK3CA gene, describe high-depth next-generation or ultradeep sequencing, and state the laboratory's validated limit for detecting low-level mosaic variants. It should also report the VAF and include a clinician's interpretation of how the result fits the person's physical findings. A single sequencing-depth number is not enough to judge test performance.

Get notified when new evidence is published on Segmental progressive overgrowth syndrome with fibroadipose hyperplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.

    Kuentz P, St-Onge J, Duffourd Y, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(9)):989-997 doi:10.1038/gim.2016.220.

    PMID: 28151489
  2. 2

    Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.

    Mussa A, Leoni C, Iacoviello M, et al.

    Journal of medical genetics 2023; (60(2)):163-173 doi:10.1136/jmedgenet-2021-108093.

    PMID: 35256403
  3. 3

    Mosaic Variant in Unilateral Woolly Hair in a Girl With PIK3CA-Related Overgrowth Spectrum.

    Tanaka R, Takeguchi R, Akaba Y, et al.

    Congenital anomalies 2026; (66(1)):e70066.

    PMID: 42230161
  4. 4

    Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.

    Tian W, Sun L, Zhang Q, et al.

    Molecular genetics and genomics : MGG 2022; (297(2)):387-396 doi:10.1007/s00438-022-01853-x.

    PMID: 35122151
  5. 5

    Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.

    Brouillard P, Schlögel MJ, Homayun Sepehr N, et al.

    Orphanet journal of rare diseases 2021; (16(1)):267 doi:10.1186/s13023-021-01898-y.

    PMID: 34112235
  6. 6

    Deep Intramuscular Vascular Malformations in Pediatric Klippel-Trenaunay Syndrome Mimicking Maffucci Syndrome: A Case Report.

    Shah SS, Sajid B, Tabassum M, et al.

    Clinical case reports 2026; (14(11)):e73825 doi:10.1002/ccr3.73825.

    PMID: 42964341
  7. 7

    Radiological evaluation of the natural history of PIK3CA-related overgrowth spectrum (PROS).

    Fraissenon A, Morin G, Boddaert N, et al.

    European journal of radiology 2026; (204()):113108 doi:10.1016/j.ejrad.2026.113108.

    PMID: 42520377
  8. 8

    Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature and peripheral venous dilatation: parks weber syndrome or PROS?

    Su LX, Sun Y, Wang Z, et al.

    Hereditas 2022; (159(1)):1 doi:10.1186/s41065-021-00217-6.

    PMID: 34980271
  9. 9

    Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.

    Keppler-Noreuil KM, Lozier J, Oden N, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(4)):571-581 doi:10.1002/ajmg.c.31735.

    PMID: 31490637
  10. 10

    Wound-Healing Problems Associated with Combined Vascular Malformations in Klippel-Trenaunay Syndrome.

    Ishikawa K, Yamamoto Y, Funayama E, et al.

    Advances in wound care 2019; (8(6)):246-255 doi:10.1089/wound.2018.0835.

    PMID: 31832274
  11. 11

    Detailed analysis of phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndrome caused by somatic mosaicism of PIK3CA mutations.

    Park HJ, Shin CH, Yoo WJ, et al.

    Orphanet journal of rare diseases 2020; (15(1)):205 doi:10.1186/s13023-020-01480-y.

    PMID: 32778138
  12. 12

    Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.

    Piacitelli AM, Jensen DM, Brandling-Bennett H, et al.

    American journal of medical genetics. Part A 2018; (176(11)):2301-2308 doi:10.1002/ajmg.a.40487.

    PMID: 30063105
  13. 13

    PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib.

    Pagliazzi A, Oranges T, Traficante G, et al.

    Frontiers in pediatrics 2021; (9()):732836 doi:10.3389/fped.2021.732836.

    PMID: 34568242
  14. 14

    Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum.

    Hucthagowder V, Shenoy A, Corliss M, et al.

    Clinical genetics 2017; (91(1)):79-85 doi:10.1111/cge.12819.

    PMID: 27307077

This page explains PROS diagnostic testing and pathology reports for educational purposes and does not replace medical advice. A genetics or vascular-anomalies team should interpret your results and decide whether tissue testing or additional imaging is appropriate.